Literature DB >> 6520070

Treatment of antibiotic-associated colitis with vancomycin.

R Fekety, J Silva, B Buggy, H G Deery.   

Abstract

Sixty-five patients were treated with oral vancomycin for Clostridium difficile colitis associated with treatment of infection by antibiotics. Colitis was confirmed by endoscopy in patients with diarrhoea and positive tests on diarrhoeal stools for Cl. difficile and/or its cytotoxin or, if endoscopy could not be performed, by the presence of fever and peripheral or faecal leucocytosis. Vancomycin dosage ranged from 125 to 500 mg four times daily for an average of about ten days. The mean duration of diarrhoea after starting therapy was four days; abdominal pain and fever usually resolved in two or three days. Post-treatment carriage of Cl. difficile was common. Eighteen per cent of patients developed a recurrence of colitis after treatment was discontinued, but responded to treatment with oral vancomycin, metronidazole, or bacitracin. After comparison of our results with those reported by others we concluded that vancomycin remains the treatment of choice for patients who are acutely and severely ill with Cl. difficile.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6520070     DOI: 10.1093/jac/14.suppl_d.97

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Isolation and characterization of temperate bacteriophages of Clostridium difficile.

Authors:  Shan Goh; Thomas V Riley; Barbara J Chang
Journal:  Appl Environ Microbiol       Date:  2005-02       Impact factor: 4.792

Review 3.  Resistance to vancomycin and teicoplanin: an emerging clinical problem.

Authors:  A P Johnson; A H Uttley; N Woodford; R C George
Journal:  Clin Microbiol Rev       Date:  1990-07       Impact factor: 26.132

4.  Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.

Authors:  R P Bolton; M A Culshaw
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

5.  A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Authors:  Jennifer Peppe; Andrew Porzio; David M Davidson
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

6.  In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.

Authors:  F Biavasco; E Manso; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

7.  Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea.

Authors:  F de Lalla; R Nicolin; E Rinaldi; P Scarpellini; R Rigoli; V Manfrin; A Tramarin
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  Treatment of Clostridium difficile-associated disease with teicoplanin.

Authors:  F de Lalla; G Privitera; E Rinaldi; G Ortisi; D Santoro; G Rizzardini
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

9.  Antimicrobial activity of aridicins, novel glycopeptide antibiotics with high and prolonged levels in blood.

Authors:  S F Grappel; A J Giovenella; L Phillips; D H Pitkin; L J Nisbet
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

Review 10.  WSES guidelines for management of Clostridium difficile infection in surgical patients.

Authors:  Massimo Sartelli; Mark A Malangoni; Fikri M Abu-Zidan; Ewen A Griffiths; Stefano Di Bella; Lynne V McFarland; Ian Eltringham; Vishal G Shelat; George C Velmahos; Ciarán P Kelly; Sahil Khanna; Zaid M Abdelsattar; Layan Alrahmani; Luca Ansaloni; Goran Augustin; Miklosh Bala; Frédéric Barbut; Offir Ben-Ishay; Aneel Bhangu; Walter L Biffl; Stephen M Brecher; Adrián Camacho-Ortiz; Miguel A Caínzos; Laura A Canterbury; Fausto Catena; Shirley Chan; Jill R Cherry-Bukowiec; Jesse Clanton; Federico Coccolini; Maria Elena Cocuz; Raul Coimbra; Charles H Cook; Yunfeng Cui; Jacek Czepiel; Koray Das; Zaza Demetrashvili; Isidoro Di Carlo; Salomone Di Saverio; Irina Magdalena Dumitru; Catherine Eckert; Christian Eckmann; Edward H Eiland; Mushira Abdulaziz Enani; Mario Faro; Paula Ferrada; Joseph Derek Forrester; Gustavo P Fraga; Jean Louis Frossard; Rita Galeiras; Wagih Ghnnam; Carlos Augusto Gomes; Venkata Gorrepati; Mohamed Hassan Ahmed; Torsten Herzog; Felicia Humphrey; Jae Il Kim; Arda Isik; Rao Ivatury; Yeong Yeh Lee; Paul Juang; Luis Furuya-Kanamori; Aleksandar Karamarkovic; Peter K Kim; Yoram Kluger; Wen Chien Ko; Francis D LaBarbera; Jae Gil Lee; Ari Leppaniemi; Varut Lohsiriwat; Sanjay Marwah; John E Mazuski; Gokhan Metan; Ernest E Moore; Frederick Alan Moore; Carl Erik Nord; Carlos A Ordoñez; Gerson Alves Pereira Júnior; Nicola Petrosillo; Francisco Portela; Basant K Puri; Arnab Ray; Mansoor Raza; Miran Rems; Boris E Sakakushev; Gabriele Sganga; Patrizia Spigaglia; David B Stewart; Pierre Tattevin; Jean Francois Timsit; Kathleen B To; Cristian Tranà; Waldemar Uhl; Libor Urbánek; Harry van Goor; Angela Vassallo; Jean Ralph Zahar; Emanuele Caproli; Pierluigi Viale
Journal:  World J Emerg Surg       Date:  2015-08-20       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.